Faron Pharmaceuticals Oyj

08/04/2026 | Press release | Distributed by Public on 08/04/2026 07:02

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

English Published: 2026-08-04 15:00:00 CEST Faron Pharmaceuticals Oy - Major shareholder announcements

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | August 04, 2026 at 16:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights X
Other (please specify) iii: Amortisation of the First and Second Tranche Bonds with treasury shares X
3. Details of person subject to the notification obligation iv
Name Faron Pharmaceuticals Ltd
City and country of registered office (if applicable) Turku, Finland
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi: 3.8.2026
6. Date on which issuer notified (DD/MM/YYYY): 3.8.2026
7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2) 		Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 9.37%
9.37% 21,342,679
Position of previous notification (if
applicable) 		10.97%
10.97%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible) 		Number of voting rights ix % of voting rights
Direct
(DTR5.1) 		Indirect
(DTR5.2.1) 		Direct
(DTR5.1) 		Indirect
(DTR5.2.1)
FI4000153309 21,342,679
9.37%










SUBTOTAL 8. A 21,342,679 9.37%


B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x 		Exercise/
Conversion Period xi 		Number of voting rights that may be acquired if the instrument is
exercised/converted. 		% of voting rights

















SUBTOTAL 8. B 1



B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x 		Exercise/
Conversion Period xi 		Physical or cash
Settlement xii 		Number of voting rights % of voting rights





















SUBTOTAL 8.B.2



9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii x
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Faron Pharmaceuticals Ltd 9.37%
9.37%

















10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information xvi
3.8.2026 Company announcement: Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
Place of completion Turku, Finland
Date of completion 3.8.2026
Company News Subscribe European Market Activity Nasdaq Europe
© 2026, Nasdaq, Inc. All Rights Reserved.
Faron Pharmaceuticals Oyj published this content on August 04, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 04, 2026 at 13:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]